DIRS.INFO The most relevant business & tech news

☆ Blackstone explores sale of Anthos Therapeutics -sources
▼ + stars: | 2023-12-04 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

Signage is seen outside the Blackstone Group headquarters in New York City, U.S., January 18, 2023. Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added. Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential. Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.

Persons: Blackstone, Anthos, Bayer, Eliquis, David Carnevali, Leslie Adler Organizations: Blackstone Group, REUTERS, Blackstone Inc, Anthos Therapeutics, Novartis AG, Novartis, Myers Squibb, Alnylam Pharmaceuticals, Thomson Locations: New York City, U.S, Cambridge , Massachusetts, Anthos, Bristol, German, New York

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
▼ + stars: | 2023-12-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

BRAZIL - 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest company to attempt to unseat Novo Nordisk and Eli Lilly's dominance within the global weight-loss drugs market. The U.S. takeover target's early-stage technology could help crack highly prized oral obesity treatments, Roche Pharmaceuticals CEO Teresa Graham said Monday, but it may be several years before the drugs are widely available. The deal will provide Roche access to Carmot's current research and development portfolio, including all clinical and preclinical assets. Shares of the Swiss company, which have been in the doldrums this year, were up 2.25% following the news of the acquisition.

Persons: HoffmannLa Roche, Rafael Henrique, Roche, Eli Lilly's, Teresa Graham, we'll, Graham, CNBC's Julianna Tatelbaum, Eli Lilly's Mounjaro Organizations: Getty Images, Carmot Therapeutics, Novo Nordisk, U.S, Roche Pharmaceuticals, Roche Locations: BRAZIL, Swiss, California

☆ 2023 has been an AI feeding frenzy, here are the startups that attracted the most investment this year
▼ + stars: | 2023-12-04 | by ( Darius Rafieyan | ) www.businessinsider.com time to read: +7 min

Despite an overall slump in startup funding, 2023 saw a scramble among investors to pour money into AI and machine learning startups. And the company's star still appears to be rising, despite a messy leadership struggle that recently spilled into public view. Meanwhile OpenAI's perennial rival Anthropic attracted multi-billion dollar investments from both Google and Amazon to fund a competing AI model known as Claude. At the same time legacy companies from John Deere to accounting firm PwC played up their AI bona fides to capitalize on the hype. The list doesn't include startups who have not publicly released the amount of their funding rounds.

Persons: OpenAI, Anthropic, Claude, Databricks, John Deere, PwC, Fresh Organizations: Microsoft, Google, Alpha, Technology, Monogram, Sigma, Lambda, Helsing, Metals, Eagle Eye, Amelia, Asimov, Farmers Business, Harbinger, Prins, Silo, Mistral, Alto, AMP, Management Software, Universal, Coro, Kodiak Robotics, Aerospace, Defense, Sana, Corti, Kyte, Mitra, Tech, Boss Digital Technology, Halcyon, & $ Locations: PitchBook

☆ Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. The SPDR S&P Biotech ETF , which focuses on small and midsize biotech companies, rose 3% Thursday. Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price.

Persons: AbbVie, ImmunoGen, Michael Schmidt Organizations: Biotech, Mersana Therapeutics, ADC Therapeutics, P Biotech ETF, Nasdaq Biotechnology, ImmunoGen, Pfizer, Merck, CNBC PRO Locations: ADCs

☆ Cathie Wood’s Innovation ETF is up more than 30% in November, on pace for its best month ever
▼ + stars: | 2023-11-30 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange on Feb. 27, 2023. Wood's flagship Ark Innovation ETF (ARKK) has rallied 32% this month, on pace to score its strongest month ever since its inception in 2014. The fund rebounded dramatically from three straight months of losses, pushing 2023 gains to 48%. Cathie Wood is about to notch her best month ever as her holdings of innovative technology stocks roared back from steep losses amid declining Treasury yields in November. Driving the innovation fund higher this month have been biotech names CRISPR Therapeutics and Twist Bioscience , along with Roku , Coinbase , Block and Shopify , which are all up at least 50%.

Persons: Cathie Wood, ARKK, Wood Organizations: Ark Invest, CNBC, New York Stock Exchange, Innovation, CRISPR Therapeutics, Twist, Ark, CNBC PRO Locations: outflows

☆ Here are Tuesday's biggest analyst calls: Apple, Rivian, Nvidia, Boeing, Affirm, Datadog, Amazon & more
▼ + stars: | 2023-11-28 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: UBS downgrades ChargePoint to neutral from buy UBS said it's cautious on the EV charging company's growth outlook. " Citi reiterates Nvidia as buy Citi said it's sticking with its buy rating on shares of Nvidia. " Wells Fargo downgrades Booz Allen Hamilton to equal weight from overweight Wells said investors should wait for a better entry point for the defense contractor. Raymond James upgrades Crocs to strong buy from outperform Raymond James said it sees an attractive entry point for the show company. Wells Fargo reiterates Amazon as overweight Wells said international trends for Amazon remain healthy.

Persons: UBS downgrades ChargePoint, it's, Wells, Booz Allen Hamilton, Bernstein, Raymond James, Crocs, CROX's, Estee Lauder, Jefferies, underperform Jefferies, Evercore, Rivian, Piper Sandler downgrades Shopify, Piper, Piper Sandler, Canaccord, TD Cowen, Datadog, TD, Truist, it's bullish, Ingersoll Rand Organizations: UBS downgrades, UBS, JPMorgan, Apple, Citi, Nvidia, HSBC, RBC, Boeing, Lexeo Therapeutics, Bank of America, Virtu, Logistics, Industry Locations: U.S, DDOG, India, Ingersoll

☆ Stocks making the biggest moves midday: PDD Holdings, Micron, Boeing, Twilio and more
▼ + stars: | 2023-11-28 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Check out the companies making the biggest moves midday: PDD Holdings — U.S.-listed shares of the international ecommerce company jumped more than 18% after PDD posted a big earnings and revenue beat . PDD, the parent of Pinduoduo and Temu, reported a whopping 94% year-over-year increase in revenue for its third quarter. Micron Technology — Micron Technology's stock fell nearly 3% even after the memory chipmaker boosted its revenue guidance for its fiscal first-quarter. Twilio — The enterprise software stock jumped nearly 4% after CNBC reported activist investor Anson Funds has built a stake in Twilio. U.S. Steel — Shares added 1.7% in midday trading.

Persons: PDD, Ken Herbert, Twilio, Anson, Crocs, Raymond James, it's, CNBC's David Faber, Ogsiveo, Dow, Carlyle, Jefferies, nLight, Alex Harring, Samantha Subin, Lisa Han, Spencer Kimball, Jesse Pound Organizations: PDD Holdings —, Micron Technology, Micron, Boeing —, RBC Capital Markets, CNBC, . Steel, Steel, U.S . Steel, SpringWorks Therapeutics, Food and Drug Administration, Therapeutics, Carlyle, Dow Jones Indices, underperform Locations: Ireland, China, Twilio, Cleveland, United States

☆ This biotech stock targeting genetically driven diseases could nearly double, predicts JPMorgan
▼ + stars: | 2023-11-28 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Lexeo Therapeutics ' stock could nearly double as its gene therapies advance through its pipeline, according to JPMorgan. That implies a potential upside of nearly 82% from the stock's Monday closing price of $11. LXEO ALL mountain Lexeo Therapeutics all-time stock chart Analyst Tessa Romero cited Lexeo Therapeutics' lead cardiac therapy, LX2006, as a catalyst for the stock. The gene therapy is delivered to body tissues through an adeno-associated virus vector and it targets a rare genetic heart disorder called Friedreich's ataxia cardiomyopathy. The firm is also evaluating a similar type of gene therapy, LX2020, to treat cases of PKP2-ACM, another kind of inherited heart disease.

Persons: Tessa Romero, Lexeo, Romero, LX2020, LX1001, – LX2006, Michael Bloom Organizations: Therapeutics, JPMorgan, Lexeo Therapeutics, ACM, ~$ Locations: U.S

The full benefit for these Indian manufacturers will not be immediate, said Peter DeYoung, CEO of Piramal Pharma Solutions. Nimgaonkar said Indian CDMOs need to do more to ensure their reputation on quality standards matches Western and Chinese ones. The Indian CDMOs told Reuters that their facilities are routinely inspected by the FDA. Aragen counts seven of the 10 biggest pharma companies as clients, he said, declining to name them. "New biotechs are deciding to put eggs in both the Indian and China baskets from the start," Subramanian said.

Persons: Trump, Tommy Erdei, Ashish Nimgaonkar, Nimgaonkar, Sai, Peter DeYoung, Helen Chen, CDMOs, Piramal, DeYoung, Ramesh Subramanian, Subramanian, Maggie Fick, Andrew Silver, Michele Gershberg, Catherine Evans Organizations: Jefferies, Glyscend Therapeutics, Reuters, Sciences, Piramal Pharma, Sai Life Sciences, Western pharma, Piramal Pharma Solutions, L.E.K, Consulting, pharma, U.S . Food, Drug Administration, FDA, Thomson Locations: China, India, SHANGHAI, HYDERABAD, U.S, Shanghai, United States, London, Hyderabad

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing RightsNov 27 (Reuters) - The U.S. health regulator on Monday approved SpringWorks Therapeutics' (SWTX.O) drug for treating adult patients with desmoid tumors, making it the first approved treatment for this type of non-cancerous soft-tissue growth. The brokerage estimates U.S. sales of $3 million in 2023 and $79 million in 2024 and peak sales of $544 million in 2032. Desmoid tumors are rare, abnormal non-cancerous growths that occur in connective tissues and are associated with a high rate of recurrence. An estimated 1,650 people in the U.S. are diagnosed with desmoid tumors each year, according to data from the National Institutes of Health.

Persons: Andrew Kelly, Saqib Islam, Ogsiveo, Cowen, Yaron, Islam, Pratik Jain, Christy Santhosh, Shilpi Majumdar, Shailesh Organizations: Food and Drug Administration, FDA, REUTERS, Therapeutics, Food, National Institutes of Health, Thomson Locations: White Oak , Maryland, U.S, United States, Bengaluru

☆ Forget Big Tech? Fund manager names 6 lesser-known tech stocks to buy instead
▼ + stars: | 2023-11-22 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +5 min

One portfolio manager, however, is shifting his focus to other tech players — particularly small mid-cap names. His comments come despite the sharp gains registered by big tech stocks which pushed the price-to-earnings ratio of the S & P 500 index to around 20 times. By contrast, the ratio is trading below 14 times when the seven Big Tech stocks are excluded, he noted. Another stock in Kharmandarian's AI and Robotics Fund fund is cybersecurity firm Crowdstrike . Electronic Design Automation Another theme on Kharmandarian's watchlist is electronic design automation — specifically companies designing the latest generations of semiconductors.

Persons: Karen Kharmandarian, Kharmandarian, bullish, Splunk Organizations: Big Tech, Apple, Microsoft, Nvidia, Tesla, Thematics Asset Management, CNBC, Robotics Fund, Cisco Systems, Cadence Design Systems, Pharmaceuticals, BioXcel Therapeutics

☆ Can you hack your brain? These companies are driving innovation in the field of brain stimulation
▼ + stars: | 2023-11-21 | by ( Pia Singh | ) www.cnbc.com time to read: +12 min

These forms of deep brain stimulation require a surgical procedure during which electrodes — which generate electrical impulses to control any abnormal brain activity — are implanted into certain areas of the brain. With enough advancement in the field, doctors expect brain stimulation techniques for both severe disorders and health-and-wellness purposes will ultimately become noninvasive. Three major players There are only three companies with FDA-approved deep brain stimulation, or DBS, treatments: Medtronic , Abbott Laboratories and Boston Scientific . The spinal cord stimulation, or SCS, business is a hotbed of innovation right now, deep brain stimulation also is a key area." There is still plenty of doubt, however, about the efficacy of at-home brain stimulation devices, which offer a less direct approach to brain stimulation and don't always require FDA oversight.

Persons: —, Bernstein, Lee Hambright, Hambright, Ali Rezai, Medtronic, Abbott, Rezai, Morningstar, Debbie Wang, Wang, Elon Musk, it's Elon Musk's, Casey Halpern, it's, Halpern, Taiwan's Organizations: Drug Administration, FDA, Abbott Laboratories, Boston, Rockefeller Neuroscience, West Virginia University, American Neuromodulation Society, Boston Scientific, DBS, FactSet, Neuroscience, BCI, University of Pennsylvania, TMS Locations: neuromodulation

Several executives committed their own, personal money to buying their company's stock this week. CNBC Pro screened for the five U.S. companies with the biggest insider buying activity over the past week, using data from VerityData. Intel — Director Lip-Bu Tan purchased 66,000 shares at an average price of $37.84 for a total of $2.5 million. Opko Health — CEO Phillip Frost bought 1 million shares at $1.27 apiece in a "high IQ" buy for a total of $1.27 million. Another notable insider purchase this week came from SolarEdge Technologies ' director Avery Moore, who bought about 15,000 shares at an average price of $70.96 for a total of $1.09 million.

Persons: Seifi Ghasemi, Tan, Kristina Burow, Phillip Frost, Orlando Carvalho, Frost, Opko, Carvalho, FactSet, Avery Moore, SolarEdge Organizations: CNBC Pro, Air Products, Chemicals, Intel, Therapeutics, Health, Mercury Systems, SolarEdge Technologies

LONDON (AP) — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. The agency approved the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy. Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.

Persons: ”, Helen O'Neill Organizations: Medicines and Healthcare Regulatory Agency, Vertex Pharmaceuticals, CRISPR Therapeutics, Helen O'Neill of University College London, Medicines, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Europe, CRISPR, South Asian, Britain, U.S, Africa, India, Eastern

☆ Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
▼ + stars: | 2023-11-16 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: +1 min

Regulators in Britain on Thursday approved the first treatment derived from CRISPR, the revolutionary gene-editing method. Called Casgevy, the treatment is intended to cure sickle-cell disease and a related condition, beta thalassemia. The companies anticipate that the Food and Drug Administration will approve Casgevy for sickle-cell patients in the United States in early December. The agency will decide on approval for beta thalassemia next year. That treatment does not rely on gene editing, insteading using a method that inserts new DNA into the genome.

Organizations: Vertex Pharmaceuticals, CRISPR Therapeutics, and Drug, Bluebird Bio Locations: Britain, Boston, Switzerland, United States, Somerville, Mass

☆ David Einhorn, who is trouncing the market this year, bought a small cap crude oil play
▼ + stars: | 2023-11-15 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

David Einhorn's Greenlight Capital made several bets in energy and health care during the third quarter, according to a new securities filing. That position was worth $65.2 million. Greenlight also bought up shares in biotech names Gain Therapeutics and Coya Therapeutics , increasing those stakes by 7.7% and 19.2%, respectively. The fund's largest position, homebuilding stock Green Brick Partners , was worth more than $512 million as of the end of September. Greenlight has soared past the broader market this year, returning 12.9% in the third quarter to bring its 2023 gains to more than 27%.

Persons: David Einhorn's, Einhorn, Russia's, Greenlight Organizations: Holdings, Securities, Exchange, Southwestern Energy, Consol Energy, Therapeutics, Coya Therapeutics, Green Brick Partners, Kyndryl Holdings Locations: Israel, Ukraine, U.S

Tuesday started with Nvidia getting more praise from one analyst, and a battery stock downgrade. She has a price target of $40 on shares, which suggests 20.3% upside potential from where shares closed on Monday. The firm initiated the stock with a buy rating and $125 price target, which suggests 7% upside from Monday's close. "3Q brings a narrative change in FREY's outlook with new risks to tech, strategy and funding that's been appropriately discounted by the stock market. He also slashed his price target to $2 from $13, which suggests 14.3% upside from Monday's close.

Persons: Tuesday, Morgan Stanley, Freyr, Paul Matteis, Matteis, Vistagen, — Hakyung Kim, BeautyHealth, Allen Gong, Gong, Benjamin Soff, Soff, Bernstein, Kraft Heinz, Alexia Howard, Howard, Miguel Patricio, Roth, Suji Desilva, Desilva, Morgan Stanley downgrades Freyr Battery Morgan Stanley isn't, that's, FREY, Adam Jonas, Jonas, Vivek Arya, — Fred Imbert Organizations: CNBC, Nvidia, Bank of America, Therapeutics Biotechnology, Vistagen Therapeutics, JPMorgan, Deutsche Bank, Rockstar, Kraft, Kraft Heinz, AMD, Investment, Freyr's, Nvidia Bank of America Locations: U.S, Monday's, Freyr's Norwegian

☆ Cramer's Lightning Round: 'Too much hype' for C3.ai
▼ + stars: | 2023-11-14 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon HubSpot's year-to-date stock performance. Stock Chart Icon Stock chart icon Albemarle's year-to-date stock performance. Stock Chart Icon Stock chart icon Chewy's year-to-date stock performance. Stock Chart Icon Stock chart icon Leonardo DRS's year-to-date stock performance. Stock Chart Icon Stock chart icon CrowdStrike's year-to-date stock performance.

Persons: it's, Leonardo DRS's, Leonardo DRS, Brown, Forman, I've, They're, I'm, they're, Tom Siebel, George Kurtz Organizations: New York Community, New York Community Bancorp, Therapeutics, Sarepta Therapeutics, US Bancorp

☆ Stocks making the biggest moves premarket: Fisker, Kraft Heinz, Home Depot and more
▼ + stars: | 2023-11-14 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Fisker — The electric vehicle startup company plummeted more than 18% after missing on third-quarter earnings forecasts and reporting light vehicle deliveries. The company noted that the pace of vehicle deliveries accelerated near the end of the quarter, however. Kraft Heinz — The food and beverage giant added 1.6% in premarket trading after Bernstein upgraded the stock to outperform from market perform. Home Depot — The home improvement retail stock gained nearly 1% after the company posted third-quarter earnings and revenue that beat expectations. Take-Two Interactive Software — The video game company added 2.2% on the back of an upgrade from Deutsche Bank.

Persons: Kraft Heinz, Bernstein, —, Jesse Pound, Brian Evans, Michelle Fox Theobald Organizations: Therapeutics, Deutsche Bank Locations: U.S

☆ Zepbound: The newest obesity medication explained by an expert
▼ + stars: | 2023-11-14 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

CNN —The US Food and Drug Administration approved the medication Zepbound last week to treat chronic obesity. Tirzepatide joins a similar medication called semaglutide that was also initially developed for diabetes treatment under the name Ozempic and has since been approved to treat obesity under the name Wegovy. Studies on both have shown high effectiveness in treating diabetes and obesity. The injectable medication Zepbound, manufactured by Eli Lilly, was approved by the FDA on November 8 to treat chronic obesity. Note that technically, the versions of the medicines someone needs for obesity treatment are Zepbound and Wegovy.

Persons: Eli Lilly, Tirzepatide, —, Leana Wen, Wen, Zepbound, Ozempic Organizations: CNN, Food and Drug Administration, George Washington University Milken Institute School of Public Health, FDA, The New England, of Medicine, JAMA, Novo Nordisk, semaglutide, BMI Locations: The, tirzepatide, Wegovy

☆ Stocks making the biggest moves midday: Home Depot, Fisker, SolarEdge and more
▼ + stars: | 2023-11-14 | by ( Brian Evans | ) www.cnbc.com time to read: +4 min

Azenta — The life science stock jumped 13% on Tuesday, a day after the company delivered its fiscal fourth-quarter report. Home Depot — Shares of the home improvement retailer jumped 6% after the company posted third-quarter earnings and revenue that beat expectations. Enphase Energy , Solar Edge , First Solar – The solar power stocks surged on Tuesday, with Enphase adding nearly 14%. Solar companies and tech stocks are sensitive to interest rates, and fare well when bond yields decline. Adobe — The software stock climbed nearly 2% in midday trading.

Persons: FactSet, Matthew Shattock, Fisker, — CNBC's Pia Singh, Alex Harring, Michelle Fox, John Rosevear, Darla Mercado Organizations: Enphase, Solar, V.F, Corp, Amazon Web Services, Therapeutics, Federal, Deutsche Bank, EV, Adobe

☆ Aclaris shares plummet on terminating development of rheumatoid arthritis drug
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +1 min

Companies Aclaris Therapeutics Inc FollowNov 13 (Reuters) - Aclaris Therapeutics (ACRS.O) on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial, sending its shares plunging 84% before the bell. The trial tested two doses of the drug, zunsemetinib, along with anti-rheumatic drug methotrexate compared to placebo and methotrexate in patients with moderate to severe rheumatoid arthritis who have inadequate response to methotrexate alone. There was no notable differentiation between zunsemetinib and placebo across any measures of efficacy at 12 weeks, the company said. The company will also be halting enrollment in an ongoing mid-stage trial studying the drug in psoriatic arthritis. The drug developer said it is also studying its drug ATI-1777 in patients with moderate to severe atopic dermatitis which is currently in mid-stage trial.

Persons: Sriparna Roy, Maju Samuel Organizations: Aclaris Therapeutics, ATI, Thomson Locations: Bengaluru

☆ New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
▼ + stars: | 2023-11-12 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: +1 min

The handful of patients had severe heart disease that had caused chest pain and heart attacks. After trying available cholesterol-lowering medications, they could not get their cholesterol as low as cardiologists recommended. So they volunteered for an experimental cholesterol-lowering treatment using gene editing that was unlike anything tried in patients before. Each had a genetic abnormality, familial hypercholesterolemia, that affects around one million people in the United States. In the United States alone, more than 800,000 people have heart attacks each year.

Organizations: Verve Therapeutics, American Heart Association Locations: Boston, United States

Search resuls for: "THERAPEUTICS"

25 mentions found